Pharmaceuticals company JCR Pharmaceuticals Co, Ltd (TOKYO: 4552) and Modalis Therapeutics Corporation (TOKYO: 4883), a research and development company, on Monday announced the successful validation of the initial proof of concept in their joint research for a novel gene therapy targeting a central nervous system (CNS) disease.
Based on the success to date, both companies have agreed to proceed to the next phase, entering into a new joint research agreement to conduct pre-clinical studies.
This collaboration leverages JCR's proprietary J-Brain Cargo technology, designed to cross the blood-brain barrier, alongside Modalis' CRISPR-GNDM platform, which modulates gene expression without altering DNA sequences. This phase aims to develop a gene therapy that offers improved efficacy, safety and a less invasive treatment option via intravenous injection.
The partnership, which began in December 2023, represents a significant step forward in gene therapy development. While the transition to the next phase is positive news, it is expected to have only a minor impact on both companies' consolidated financial results for their respective fiscal years (JCR's fiscal year ends March 2025, Modalis' ends December 2025).
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease
Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc
Neuraxpharm acquires Provigil and Nuvigil to expand CNS portfolio
Nuvation Bio secures NMPA approval for taletrectinib in China
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities
Newron and EA Pharma sign licensing deal for Evenamide in Asia
Cybin selects Facet Life Sciences as US regulatory partner
GC Biopharma and Novel Pharma report first patient dosed in multinational trial of GC1130A
Merck's WELIREG approved in China for VHL disease
AbbVie signs new discovery, co-development and licence agreement with Gedeon Richter
JCR Pharmaceuticals showcases preclinical gene therapy advances at ESGCT Congress